These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 27780932)

  • 1. Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy.
    Ha H; Nam AR; Bang JH; Park JE; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ; Oh DY
    Oncotarget; 2016 Nov; 7(47):76604-76612. PubMed ID: 27780932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamics of Soluble Programmed Death-Ligand 1 (sPDL1) during Chemotherapy and Its Prognostic Implications in Cancer Patients: Biomarker Development in Immuno-oncology.
    Ha H; Bang JH; Nam AR; Park JE; Jin MH; Bang YJ; Oh DY
    Cancer Res Treat; 2019 Apr; 51(2):832-840. PubMed ID: 30309223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy is useful to predict a more accurate prognosis of advanced biliary tract cancer.
    Cho KM; Park H; Oh DY; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ
    Oncotarget; 2017 Jan; 8(2):2329-2341. PubMed ID: 27911876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Value of Serum Soluble Programmed Death-Ligand 1 and Dynamics During Chemotherapy in Advanced Gastric Cancer Patients.
    Park W; Bang JH; Nam AR; Jin MH; Seo H; Kim JM; Oh KS; Kim TY; Oh DY
    Cancer Res Treat; 2021 Jan; 53(1):199-206. PubMed ID: 33070562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutrophil/lymphocyte ratio as a prognostic factor in biliary tract cancer.
    McNamara MG; Templeton AJ; Maganti M; Walter T; Horgan AM; McKeever L; Min T; Amir E; Knox JJ
    Eur J Cancer; 2014 Jun; 50(9):1581-9. PubMed ID: 24630393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inflammatory markers in intrahepatic cholangiocarcinoma: Effects of advanced liver disease.
    Sellers CM; Uhlig J; Ludwig JM; Stein SM; Kim HS
    Cancer Med; 2019 Oct; 8(13):5916-5929. PubMed ID: 31429524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Programmed Death Ligand 1 Expression as a Prognostic Marker in Patients with Advanced Biliary Tract Cancer.
    Kim H; Kim J; Byeon S; Jang KT; Hong JY; Lee J; Park SH; Park JO; Park YS; Lim HY; Kang WK; Kim ST
    Oncology; 2021; 99(6):365-372. PubMed ID: 33730723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Preoperative Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios on Survival in Patients with Extrahepatic Cholangiocarcinoma.
    Kitano Y; Yamashita YI; Yamamura K; Arima K; Kaida T; Miyata T; Nakagawa S; Mima K; Imai K; Hashimoto D; Chikamoto A; Baba H
    Anticancer Res; 2017 Jun; 37(6):3229-3237. PubMed ID: 28551669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses.
    Yoon JG; Kim MH; Jang M; Kim H; Hwang HK; Kang CM; Lee WJ; Kang B; Lee CK; Lee MG; Chung HC; Choi HJ; Park YN
    Hepatology; 2021 Oct; 74(4):1914-1931. PubMed ID: 33884649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-treatment neutrophil-to-lymphocyte ratio (NLR) predicts response to anti-PD-1/PD-L1 antibody in SCLC patients at early phase.
    Xiong Q; Huang Z; Xin L; Qin B; Zhao X; Zhang J; Shi W; Yang B; Zhang G; Hu Y
    Cancer Immunol Immunother; 2021 Mar; 70(3):713-720. PubMed ID: 32910245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic role of soluble transforming growth factor-β and its correlation with soluble programmed death-ligand 1 in biliary tract cancer.
    Kim JW; Lee KH; Kim JW; Suh KJ; Nam AR; Bang JH; Jin MH; Oh KS; Kim JM; Kim TY; Oh DY
    Liver Int; 2021 Feb; 41(2):388-395. PubMed ID: 32780918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated NLR in gallbladder cancer and cholangiocarcinoma - making bad cancers even worse: results from the US Extrahepatic Biliary Malignancy Consortium.
    Beal EW; Wei L; Ethun CG; Black SM; Dillhoff M; Salem A; Weber SM; Tran T; Poultsides G; Son AY; Hatzaras I; Jin L; Fields RC; Buettner S; Pawlik TM; Scoggins C; Martin RC; Isom CA; Idrees K; Mogal HD; Shen P; Maithel SK; Schmidt CR
    HPB (Oxford); 2016 Nov; 18(11):950-957. PubMed ID: 27683047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High pretreatment neutrophil-lymphocyte ratio predicts recurrence and poor prognosis for combined small cell lung cancer.
    Shao N; Cai Q
    Clin Transl Oncol; 2015 Oct; 17(10):772-8. PubMed ID: 26243392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of preoperative neutrophil/lymphocyte ratio and platelet/lymphocyte ratio in patients with gallbladder carcinoma.
    Zhang Y; Jiang C; Li J; Sun J; Qu X
    Clin Transl Oncol; 2015 Oct; 17(10):810-8. PubMed ID: 26077119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the effectiveness of chemotherapy combined with immunotherapy and chemotherapy alone in advanced biliary tract cancer and construction of the nomogram for survival prediction based on the inflammatory index and controlling nutritional status score.
    Zhang Z; Wang D; Zhang J; Ruan Y; Zhao L; Yang L; Liu Z; Yang L; Lou C
    Cancer Immunol Immunother; 2023 Nov; 72(11):3635-3649. PubMed ID: 37668711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic immune-inflammation index for predicting prognosis of colorectal cancer.
    Chen JH; Zhai ET; Yuan YJ; Wu KM; Xu JB; Peng JJ; Chen CQ; He YL; Cai SR
    World J Gastroenterol; 2017 Sep; 23(34):6261-6272. PubMed ID: 28974892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict chemotherapy outcomes and prognosis in patients with colorectal cancer and synchronous liver metastasis.
    Wu Y; Li C; Zhao J; Yang L; Liu F; Zheng H; Wang Z; Xu Y
    World J Surg Oncol; 2016 Nov; 14(1):289. PubMed ID: 27852294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic immune-inflammation index as a prognostic marker for distal cholangiocarcinoma.
    Terasaki F; Sugiura T; Okamura Y; Ito T; Yamamoto Y; Ashida R; Ohgi K; Uesaka K
    Surg Today; 2021 Oct; 51(10):1602-1609. PubMed ID: 34142236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutrophil to lymphocyte ratio as a potential predictive marker for treatment with pembrolizumab as a second line treatment in patients with non-small cell lung cancer.
    Petrova MP; Eneva MI; Arabadjiev JI; Conev NV; Dimitrova EG; Koynov KD; Karanikolova TS; Valev SS; Gencheva RB; Zhbantov GA; Ivanova AI; Sarbianova II; Timcheva CV; Donev IS
    Biosci Trends; 2020 Mar; 14(1):48-55. PubMed ID: 32023563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio associated with prognosis in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab?
    Ulas A; Avci N; Kos T; Cubukcu E; Olmez OF; Bulut N; Degirmenci M
    J BUON; 2015; 20(3):714-22. PubMed ID: 26214622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.